Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer
Bas W.G. van Rhijn(The Netherlands Cancer Institute), Alexandre R. Zlotta(Mount Sinai Hospital), Tahlita C.M. Zuiverloon(Erasmus MC), Ellen C. Zwarthoff(Erasmus MC), Bharati Bapat(Mount Sinai Hospital), Theodorus van der Kwast(Erasmus MC), Neil Fleshner(University of Toronto), André N. Vis(Hôpitaux Universitaires Henri-Mondor), Peter J. Boström(University of Turku), Chris H. Bangma(Erasmus University Rotterdam), Madelon N.M. van der Aa(Erasmus MC), Sultan S. Alkhateeb(Princess Margaret Cancer Centre), Liyang Liu(Mount Sinai Hospital), Michael A.S. Jewett(Princess Margaret Cancer Centre)
Cited by 64
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
|The Lancet Oncology|2010|944
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654